FIELD: pharmacy.
SUBSTANCE: compounds of 11-(4-methylpiperazin-1-yl)-7-fluoro-8-chloro-5H-dibenzo [b, e] [1,4] diazepine, 11-(piperazin-1-yl)-7-fluoro-8-chloro-5H-dibenzo [b, e] [1,4] diazepine, pharmaceutically acceptable salts, solvates or hydrates thereof are proposed to use for the manufacture of medicaments for treatment of therapy-resistant forms of schizophrenia. Pharmaceutical composition is also proposed.
EFFECT: group of inventions allows creation of an effective drug, application of which for treatment of therapy-resistant forms of schizophrenia can eliminate both positive and negative symptoms of schizophrenia and cognitive disorders, and application of which does not cause serious side effects, that limit its use, including sedation, tachycardia, orthostatism, agranulocytosis and hygrostomia.
10 cl, 5 dwg, 1 tbl, 7 ex
